CASE REPORT {#s1}
===========

A 60-year-old man presented with thoracic aortic dissection 7 years before this presentation. At the time of the dissection, he underwent repair of his ascending thoracic aorta with Hemashield graft and aortic valve resuspension; he was clinically well for the intervening 7 years. He then presented with left flank pain. Computed tomography angiogram (CTA) revealed left renal and splenic infarcts, which were felt to be the result of bland embolization originating from residual dissection flaps. He was discharged with anticoagulation.

He returned 2 months later with left arm numbness and weakness and was found to have occlusion of his left subclavian artery extending to the radial artery. He underwent extensive thromboembolectomy. The excised clot was felt to have an unusual appearance and was sent for routine bacterial culture and pathology. Findings on transthoracic echocardiogram and CTA were concerning for mural thrombus within the false lumen of the distal infrarenal abdominal aorta and adherent to the wall of the ascending aorta at the distal end of the aortic graft. Imaging also demonstrated evidence of mycotic pseudoaneurysms of the left subclavian and middle colic branch of the superior mesenteric artery and of multiple small cerebral mycotic aneurysms with punctate subacute right parietal and chronic right cerebral and precentral gyral infarcts. All of these findings raised concern for infection of his prosthetic aortic graft with septic embolization.

Aerobic and anaerobic cultures of the excised thrombus and routine blood cultures drawn at the time of his initial presentation all had no growth. Histopathology of both the brachial and radial portions of the thrombus revealed numerous fungal hyphal forms ([Figure 1](#F1){ref-type="fig"}). Morphology was consistent with hyalophyphomycosis, as the fungal elements were septate and appeared nonmelanized when stained with hematoxylin and eosin. Both acute- and right-angle branching were present, with neither predominating, and numerous dilations (varicosities) of the hyphae were visible. The latter 2 features are uncommon in *Aspergillus* and raised the suspicion of a non-*Aspergillus* hyaline mold such as *Fusarium* or *Paecilomyces* or a dematiaceous mold with nonpigmented hyphae such as *Scedosporium*. Serum beta-D-glucan and galactomannan were both greater than the upper limit of quantification ([Figure 2](#F2){ref-type="fig"}), supporting a diagnosis of extensive endovascular fungal disease.

![Histopathology from excised thrombus. A, B, Hematoxylin and eosin stain, 40× (A) and 400× (B). Numerous hyaline fungal hyphae are visible throughout the thrombus (arrowhead), some with varicosities (arrow). C, D, Gomori's methenamine silver stain, 100× (C) and 400× (D). This stain better highlights the abundant septate hyphae present (arrowhead), with occasional varicosities (arrow).](ofaa166f0001){#F1}

![Serum fungal biomarkers over time. Galactomannan and beta-D-glucan were measured in peripheral blood over time after initiation of therapy. Galactomannan is reported as an index, with 3.75 being the assay maximum and 0.5 the lower limit of detection. Beta-D-glucan is reported in pg/mL.](ofaa166f0002){#F2}

Following the return of the pathology report from the excised thrombus, additional samples were taken from a necrotic, possibly septic area of the left kidney and from a residual left upper extremity hematoma, but cultures including dedicated fungal cultures were negative. The paraffin-embedded, formalin-fixed pathology specimen of the excised thrombus was sent to the Department of Laboratory Medicine at the University of Washington for amplification and sequencing of 16S and 28S rDNA. No bacterial DNA was detected; sequencing of 28S rDNA identified *Paecilomyces variotii*.

After the renal and residual hematoma biopsies were obtained, liposomal amphotericin B 5 mg/kg/d was initiated pending sequencing results. After 4 days, in response to acute kidney injury, therapy was switched to micafungin 150 mg intravenously (IV) daily and voriconazole 300 mg twice daily (initially IV, then oral \[PO\]). When DNA sequencing results returned, given published data suggesting that posaconazole has more favorable in vitro activity against *P. variotii* \[[@CIT0022], [@CIT0023]\] voriconazole was stopped and delayed release posaconazole 300 mg PO daily was started. Micafungin was continued.

The patient was re-admitted the following month for ulnar neuropathy caused by brachial plexus compression, caused by enlargement of his left subclavian pseudoaneurysm. Posaconazole trough drawn at steady state was in the therapeutic range at 1300 ng/mL (serial levels in [Table 2](#T2){ref-type="table"}). Although beta-D-glucan levels were still greater than the upper limit of quantification, galactomannan had decreased to 2.1 ([Figure 2](#F2){ref-type="fig"}). He underwent resection of the pseudoaneurysm, repaired with carotid-distal subclavian artery prosthetic bypass graft. The procedure was complicated by recurrent laryngeal nerve injury and left posterior cerebral artery stroke. When he presented for outpatient follow-up 2 months postprocedure, his resulting hoarseness had improved and he was recovering well from his right homonymous hemianopsia. In the setting of clinical improvement and undetectable galactomannan, micafungin was discontinued even though beta-D-glucan remained greater than assay.

On continued posaconazole therapy, he has achieved clinical stability. Acknowledging the difficulty in correlating serum fungal biomarker kinetics with clinical outcomes \[[@CIT0024]\], we have nevertheless been reassured that his beta-D-glucan level gradually normalized ([Figure 2](#F2){ref-type="fig"}). To date, he has received 40 months of posaconazole 300 mg daily, with plans for life-long suppressive therapy.

DISCUSSION {#s2}
==========

We present a case of disseminated intravascular infection with *P. variotii* in an immunocompetent host. *P. variotii* intraocular lens implant--associated endophthalmitis has been associated with operating room ventilation repairs \[[@CIT0010]\]. We hypothesize that in the absence of any other predisposing factors, given this organism's environmental ubiquity \[[@CIT0003]\], the patient may have been inoculated at the time that his endovascular graft was placed, with the long clinical latency explained by the organism's low virulence in an immunocompetent host. Discussion with infection control at the institution where the graft was placed did not reveal any additional cases.

Our case is also unusual in that the microbiologic diagnosis was made by 28S rDNA sequencing. A diagnosis of fungal infection was not suspected until the pathology resulted; thus the thrombus was not sent for directed culture at the time of thromboembolectomy. Although *P. variotii* can occasionally be cultured directly from the blood \[[@CIT0018], [@CIT0019], [@CIT0021], [@CIT0025]\], it did not grow in our case. Besides *Aspergillus* spp., the galactomannan assay is known to detect other closely related molds in the family Trichocomaceae, including *Paecilomyces* and *Penicillium* spp. \[[@CIT0026], [@CIT0027]\]. Galactomannan can also occasionally cross-react with more distantly related filamentous fungi such as *Fusarium* \[[@CIT0028]\], as well as dimorphic fungi such as *Histoplasma* and *Blastomyces* \[[@CIT0026], [@CIT0029]\]. Though we find it unlikely, it remains possible that our patient's infection was caused by a more fastidious galactomannan-positive mold that also responded to posaconazole, and the 28S result reflects environmental contamination of the pathology specimen. However, the referral lab that performed the PCR-based identification advised us that they have not previously identified *P. variotii* on PCR-based tissue testing, suggesting that this is not a common contaminant. Hopefully, as fungal DNA amplification and sequencing become more common, as available reference databases expand, and as protocols for DNA extraction become more standardized, there will be more data on the sensitivity and specificity of this approach. To aid in this endeavor, consensus definitions of invasive fungal infections have recently been updated to allow classification as "proven invasive mold infection" cases in which molds are seen on pathology and fungal DNA is successfully amplified \[[@CIT0030]\].

Review of the literature is complicated by frequent microbiologic identification only to the genus level and previous taxonomic grouping of *P. variotii* with the generally more triazole-resistant (now *Purpureocillium*) *lilacinum* \[[@CIT0031], [@CIT0032]\]. Previous reports have mainly described treatment with amphotericin B formulations, often in combination with or with transition to an extended-spectrum triazole ([Table 1](#T1){ref-type="table"}). European guidelines endorse this practice \[[@CIT0033]\], but in our case, kidney injury limited duration of liposomal amphotericin B therapy to 4 days. Though in vitro activity is difficult to correlate with clinical efficacy in non-*Aspergillus* mold infections \[[@CIT0034]\] several in vitro studies of *P. variotii* have demonstrated low minimum inhibitory concentrations of echinocandins (with micafungin minimum inhibitory concentrations more favorable than those of caspofungin or anidulafungin) as well as triazoles (with posaconazole and itraconazole more active than voriconazole) \[[@CIT0021], [@CIT0035]\]. Data are scant for newer agents such as isavuconazole, but 1 study generated promising data for ibrexafungerp \[[@CIT0035]\]. In vitro synergy has not been demonstrated between echinocandins and triazoles for *P. variotii* \[[@CIT0036], [@CIT0039]\] but given the extent of the infection and our inability to facilitate surgical debulking, our patient was initially treated with both micafungin and posaconazole. The patient remains well, now \>3 years after transition to posaconazole monotherapy. His excellent outcome is striking in its contrast to those of patients with hematologic malignancy and non-*Aspergillus* mold infections \[[@CIT0034]\] and perhaps reflects his preserved immune system more than the treatment strategy used.

###### 

*Paecilomyces variotii* Infections With Treatment Outcomes

  Year                  Infection                                                                                                Organism Identification                                               Comorbidities                                                                                                       Treatment                                                                                                                                                                                                                                     Outcome
  --------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  1963 \[[@CIT0040]\]   Prosthetic mechanical mitral valve endocarditis complicated by septic emboli to spleen, kidneys, brain   Growth from blood cultures, identification on pathology               Rheumatic fever                                                                                                     Mycostatin 500~ ~000 U Q6H                                                                                                                                                                                                                    Treatment failure (death due to heart failure and lack of neurological improvement)
  1974 \[[@CIT0008]\]   Prosthetic mechanical aortic valve endocarditis                                                          Growth from blood cultures, identification on pathology               Idiopathic severe aortic insufficiency                                                                              AMB 30--50 mg QD, 5FC 2.5 g QD (ultimately discontinued due to toxicity)                                                                                                                                                                      Treatment failure (death due to heart failure and septic cerebral emboli complicated by subarachnoid hemorrhage)
  1981 \[[@CIT0041]\]   Ventriculo-peritoneal shunt infection                                                                    Growth from CSF, identification on pathology of centrifuged CSF       Obstructive hydrocephalus due to basilar artery aneurysm, DM                                                        Shunt exchange, intraperitoneal AMB 50 mg, then 100 mg                                                                                                                                                                                        Treatment failure (hemorrhage leading to death)
  1983 \[[@CIT0042]\]   Pyelonephritis                                                                                           Growth from stone sample                                              Nephrolithiasis                                                                                                     Uretero-lithotomy and antibacterials alone                                                                                                                                                                                                    Resolution
  1984 \[[@CIT0043]\]   Maxillary sinusitis                                                                                      Growth from biopsy, identification on pathology                       Recent endodontic treatment of tooth 25                                                                             Debridement alone                                                                                                                                                                                                                             Resolution
  1985 \[[@CIT0044]\]   Pneumonia                                                                                                Growth from bronchoscopy specimen                                     Hairy cell leukemia with distant steroids, chlorambucil, and cyclo-phosphamide followed by splenectomy              AMB 60 mg QD                                                                                                                                                                                                                                  Resolution
  1988 \[[@CIT0012]\]   Sphenoid sinusitis                                                                                       Growth from sphenoidotomy specimen, identification on pathology                                                                                                                           Debridement, 2 doses of AMB                                                                                                                                                                                                                   Resolution
  1991 \[[@CIT0045]\]   Peritonitis complicated by fungemia                                                                      Growth from catheter tip, blood cultures                              Chronic interstitial nephritis on PD                                                                                Catheter removal, AMB                                                                                                                                                                                                                         Resolution (with transition to HD)
  1991 \[[@CIT0046]\]   Peritonitis                                                                                              Growth from dialysate                                                 Wilms' tumor with chemoradiation complicated by CKD on PD                                                           FLC 6 mg/kg QD, then 3 mg/kg QD (failure) leading to catheter removal, AMB, FLC 3 mg/kg after TIW HD                                                                                                                                          Resolution with latter regimen (with transition to HD)
  1992 \[[@CIT0047]\]   Pneumonia                                                                                                Growth from bronchoscopy specimen                                     DM                                                                                                                  KTC 400 mg QD (failure) leading to AMB                                                                                                                                                                                                        Resolution with latter regimen
  1992 \[[@CIT0048]\]   Purulent cellulitis                                                                                      Growth from debridement sample                                        Autosomal recessive CGD on IFN-γ                                                                                    AMB 0.8 mg/kg/d for 7 wk, then ITC 100 mg BID for 1 y                                                                                                                                                                                         Resolution
  1993 \[[@CIT0049]\]   Peritonitis (4 cases)                                                                                    Growth from dialyate                                                  PD                                                                                                                  AMB intraperitoneal with failure leading to catheter removal in 2 cases, with 1 of those cases followed by total AMB 1480 mg over 4 wk; KTC 400 mg TID for 10 d, catheter removal in 1 case; KTC 200 mg QD with catheter removal in another   Resolution (with transition to HD) in all cases
  1995 \[[@CIT0050]\]   Chronic suppurative otitis media                                                                         Growth from biopsy specimen                                           Chronic amoebic dysentery                                                                                           Debridement, KTC 200 mg PO QD for 1 mo, complicated by relapse, then topical KTC cream                                                                                                                                                        Resolution
  1995 \[[@CIT0051]\]   Multifocal osteomyelitis, pneumonia                                                                      Growth from biopsy specimen                                           CGD                                                                                                                 AMB 1.5 g/kg total dose, IFN-γ then ITC 200 mg QD for 1 y                                                                                                                                                                                     Resolution
  1995 \[[@CIT0052]\]   Saline breast implant contamination                                                                      Growth from implant fluid                                                                                                                                                                 Implant removal without reimplantation                                                                                                                                                                                                        Resolution
  1996 \[[@CIT0014]\]   Peritonitis                                                                                              Growth from dialysate                                                 Hepatitis B, PD                                                                                                     Catheter removal, ITC and 5FC for 4 wk                                                                                                                                                                                                        Resolution (with resumption of PD)
  1996 \[[@CIT0053]\]   Deep SSI (complicating cesarean section)                                                                 Growth from percutaneous drainage fluid                               Gestational diabetes                                                                                                Debridement, antibacterials alone                                                                                                                                                                                                             Resolution
  1996 \[[@CIT0025]\]   Fungemia                                                                                                 Growth from blood cultures                                            Allogeneic BMT, CVC                                                                                                 CVC removal, AMB total of 641 mg, ITC 100 mg QD for 3 mo                                                                                                                                                                                      Resolution
  1998 \[[@CIT0054]\]   Peritonitis                                                                                              Growth from dialysate                                                 Chronic pyelonephritis complicated by CKD on PD                                                                     AMB 1 mg/kg/d for total dose of 2500 mg IV followed by 1 mg/L IP, catheter removal, then ITC 400 mg QD for 5 wk, then ITC 200 mg QD for 11 mo                                                                                                 Resolution (with transition to HD)
  1999 \[[@CIT0009]\]   Endogenous endophthalmitis with altered mental status                                                    Growth from vitreous aspirate                                         AML on cytotoxic chemotherapy                                                                                       AMB (25 mg/d IV, intravitreal 5 mcg/d for 3 injections, topical 2% hourly), vitrectomy                                                                                                                                                        Resolution (with preservation of remaining vision)
  2000 \[[@CIT0055]\]   Peritonitis                                                                                              Growth from dialysate                                                 14-mo-old with congenital bilateral renal hypoplasia on PD                                                          FLC 5 mg/kg/d and 50 mg/L intraperitoneally for 4 wk                                                                                                                                                                                          Resolution (with continuation on PD)
  2002 \[[@CIT0056]\]   Deep sternal SSI                                                                                         Growth from sternal debridement tissue                                Idiopathic bronchiectasis leading to bilateral lung transplantation                                                 AMB for total dose of 1500 mg, debridement, then ITC 400 mg QD for 1 y                                                                                                                                                                        Resolution
  2003 \[[@CIT0016]\]   Meningo-encephalitis                                                                                     Growth from CSF                                                       Metastatic breast cancer on cytotoxic chemotherapy, DM                                                              AMB 100, then 150, then 200 mg QD                                                                                                                                                                                                             Treatment failure (worsening mental status and gram-negative bacteremia leading to death)
  2003 \[[@CIT0057]\]   Peritonitis                                                                                              Growth from dialysate                                                 Hypertension and DM leading to CKD on PD                                                                            Catheter removal, AMB 50 mg QD, then ITC 200 mg QD                                                                                                                                                                                            Treatment failure from progressive intraperitoneal presumed *P. variotii* and polymicrobial bacterial abscesses
  2004 \[[@CIT0010]\]   Exogenous endophthalmitis                                                                                Growth from vitrectomy specimen                                       DM, IOL for cataract                                                                                                Vitrectomy, intravitreal AMB 5 mcg, KTC PO                                                                                                                                                                                                    Resolution (but with remaining visual acuity only finger counting at 2 m)
  2005 \[[@CIT0015]\]   Splenic abscess                                                                                          Growth from abscess cultures                                          X-linked CGD                                                                                                        Drainage partial splenectomy, AMB 1--1.5 mg/kg/d for 1 wk then FLC 10 mg/kg/d, 5FC 100 mg/kg/d for 14 mo                                                                                                                                      Resolution
  2005 \[[@CIT0019]\]   Fungemia                                                                                                 Growth from blood cultures                                            MM leading to autologous BMT, CVC                                                                                   AMB for 6 wk                                                                                                                                                                                                                                  Resolution
  2005 \[[@CIT0017]\]   Disseminated infection (fungemia, cellulitis, pneumonia)                                                 Growth from blood cultures, identification on skin nodule pathology   ALL on chemotherapy, on VRC prophylaxis                                                                             AMB 5 mg/kg/d for 2 mo then ITC                                                                                                                                                                                                               Resolution
  2007 \[[@CIT0058]\]   Pyelonephritis                                                                                           Growth from suprapubic urine culture and left ureteral stent          DM, nephrolithiasis with ureteral stents in place                                                                   AMB 1 mg/kg/d for 4 wk                                                                                                                                                                                                                        Resolution
  2010 \[[@CIT0059]\]   Exogenous endophthalmitis                                                                                                                                                      IOL for cataract                                                                                                    Intraocular corticosteroids and VRC                                                                                                                                                                                                           Resolution
  2013 \[[@CIT0060]\]   Pneumonia                                                                                                Growth from broncho-alveolar lavage fluid                             NHL treated with chemotherapy and allogeneic BMT complicated by presumed *Aspergillus* pneumonia, CMV esophagitis   AMB                                                                                                                                                                                                                                           Treatment failure (persistently elevated galactomannan with death from esophageal hemorrhage from CMV disease)
  2013 \[[@CIT0061]\]   Purulent nodular cellulitis                                                                              Growth from skin biopsy                                               DM                                                                                                                  ITC 200 mg BID for 6 mo                                                                                                                                                                                                                       Resolution
  2014 \[[@CIT0013]\]   Peritonitis (3 cases)                                                                                    Growth from dialysate                                                 PD, 1 also with DM                                                                                                  AMB in all cases (with 800 mg, 750 mg, 900 mg cumulative doses), additional ITC in 1 case                                                                                                                                                     Resolution (but 1 with pneumonia leading to death and the others with transition to HD)
  2015 \[[@CIT0062]\]   Pneumonia                                                                                                Growth from associated pleural effusions                              DM                                                                                                                  ITC 200 mg BID for 4 wk                                                                                                                                                                                                                       Resolution
  2015 \[[@CIT0063]\]   Peritonitis                                                                                              Growth from peritoneal fluid                                          Wison's disease necessitating liver transplant                                                                      AMB 3 mg/kg/d for 10 d combined with VRC 7 mg/kg BID (ultimately for 4 additional wk)                                                                                                                                                         Resolution (with preservation of graft function)
  2015 \[[@CIT0064]\]   Peritonitis                                                                                              Growth from dialysate                                                 PD                                                                                                                  AMB 1 mg/kg/d for 4 wk                                                                                                                                                                                                                        Resolution (with continuation of PD)
  2016 \[[@CIT0011]\]   Pan-sinusitis                                                                                            Growth from sinus tissue                                                                                                                                                                  Debridement, ITC 200 mg BID for 3 mo                                                                                                                                                                                                          Resolution
  2016 \[[@CIT0023]\]   Pneumonia                                                                                                Growth from broncho-alveolar lavage fluid culture                     AML treated with chemotherapy, haploidentical BMT                                                                   VRC (6 mg/kg BID then 4 mg/kg BID) with failure, then AMB (with infusion reaction), then POS 300 mg BID to QD                                                                                                                                 Resolution
  2017 \[[@CIT0065]\]   Peritonitis                                                                                              Growth from dialysate                                                 PD                                                                                                                  AMB 3 mg/kg/d, ITC 400 mg QD for 4 wk                                                                                                                                                                                                         Resolution (with transition to HD)
  2017 \[[@CIT0018]\]   Fungemia                                                                                                 Growth from blood cultures                                            NHL, chemotherapy complicated by HBV reactivation and liver failure requiring transplant                            AMB 5 mg/kg/d, VRC 200 mg BID for 8 d, then AFG 100 mg QD for 3 wk, then POS 200 mg suspension QID for 10 wk                                                                                                                                  Resolution
  2018 \[[@CIT0066]\]   Cutaneous ulcers                                                                                         Growth from biopsy specimens                                          Renal transplant, DM                                                                                                VRC                                                                                                                                                                                                                                           Resolution
  2019 \[[@CIT0067]\]   Pulmonary mycetoma                                                                                       Growth from broncho-alveolar lavage fluid culture                     Interstitial lung disease on prednisone                                                                             POS                                                                                                                                                                                                                                           Resolution (but with re-admission with presumed bacterial pneumonia leading to death)

Only reports with full-text articles available were included. Drug dosages were included when available.

Abbreviations: 5FC, flucytosine; AFG, anidulafungin; ALL, acute lymphocytic leukemia; AMB, amphotericin B; AML, acute myeloid leukemia; BID, twice daily; BMT, bone marrow transplant; CGD, chronic granulomatous disease; CKD, chronic kidney disease; CMV, cytomegalovirus; CSF, cerebrospinal fluid; CVC, central venous catheter; DM, diabetes mellitus; FLC, fluconazole; HD, hemodialysis; IFN-γ; interferon gamma; IOL, intraocular lens implantation; ITC, itraconazole; IV, intravenous; KTC, ketoconazole; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PD, peritoneal dialysis; PO, oral; POS, posaconazole; QD, once per day; QID, four times daily; SSI, surgical site infection; TID, three times daily; TIW, three times weekly; VRC, voriconazole.

###### 

Delayed-Release Posaconazole Therapeutic Drug Monitoring

  Date         Dose           Level        Trough   Steady State
  ------------ -------------- ------------ -------- --------------
  08/31/2016   300 mg daily   1570 ng/mL   Yes      Yes
  09/09/2016   300 mg daily   1940 ng/mL   Yes      Yes
  09/24/2016   300 mg daily   1300 ng/mL   Yes      Yes
  10/04/2016   300 mg daily   3420 ng/mL   Yes      Yes
  03/18/2017   300 mg daily   3630 ng/mL   Yes      Yes
  08/29/2017   300 mg daily   2990 ng/mL   Yes      Yes

Increasingly sophisticated molecular diagnostic approaches facilitate definitive organism identification for a growing number of unusual or difficult-to-diagnose infections. This increase in microbiologic diagnoses, in turn, offers the opportunity to expand our understanding of the spectrum of infections caused by individual organisms. Together with previously reported cases, our case suggests that *P. variotii* may have a predisposition for causing endovascular infection associated with prosthetic material in immunocompetent hosts. The case additionally illustrates that infection with low-virulence organisms can become extensive before causing symptoms that drive a clinical presentation. Failure to culture the organism despite a significant endovascular burden underlines the critical role that molecular diagnostics can play for both diagnosis and management. In this case, although our suspicion of fungal infection was very high based on pathology, sequencing results directed a change in antifungal agent. Our case additionally provides supportive evidence for the successful early use of posaconazole for endovascular *P. variotii* infection; given the substantial potential side effects of amphotericin formulations, an early change to alternate agents may have overall long-term benefit to patients.
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